Page last updated: 2024-08-22

platinum and Hodgkin Disease

platinum has been researched along with Hodgkin Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Behnia, S; Cassaday, RD; Gopal, AK; Graf, SA; Green, DJ; Holmberg, L; Libby, EN; Maloney, DG; Onishi, M; Pagel, JM; Philip, M; Press, OW; Roden, JE; Schiavo, K; Shustov, AR; Smith, SD; Till, BG	1

Other Studies

1 other study(ies) available for platinum and Hodgkin Disease

Article	Year
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. Hematological oncology, 2015, Volume: 33, Issue:4 Topics: Adolescent; Adult; Brentuximab Vedotin; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Platinum; Positron-Emission Tomography; Prognosis; Treatment Outcome; Young Adult	2015

Article

Year

Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.

Hematological oncology, 2015, Volume: 33, Issue:4

Topics: Adolescent; Adult; Brentuximab Vedotin; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Platinum; Positron-Emission Tomography; Prognosis; Treatment Outcome; Young Adult

2015